KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Share-based Compensation (2020 - 2026)

AbCellera Biologics filings provide 7 years of Share-based Compensation readings, the most recent being $12.0 million for Q1 2026.

  • Quarterly Share-based Compensation fell 18.75% to $12.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $53.0 million through Mar 2026, down 18.38% year-over-year, with the annual reading at $55.8 million for FY2025, 17.44% down from the prior year.
  • Share-based Compensation hit $12.0 million in Q1 2026 for AbCellera Biologics, down from $12.9 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $17.8 million in Q2 2024 and bottomed at $11.8 million in Q3 2022.
  • Average Share-based Compensation over 5 years is $14.6 million, with a median of $14.8 million recorded in 2025.
  • The largest annual shift saw Share-based Compensation soared 126.48% in 2022 before it decreased 20.1% in 2025.
  • AbCellera Biologics' Share-based Compensation stood at $13.3 million in 2022, then rose by 23.46% to $16.4 million in 2023, then fell by 7.43% to $15.2 million in 2024, then dropped by 15.25% to $12.9 million in 2025, then decreased by 6.9% to $12.0 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Share-based Compensation are $12.0 million (Q1 2026), $12.9 million (Q4 2025), and $13.9 million (Q3 2025).